A number of investment brokers have recently updated their price targets on shares of Aldeyra Therapeutics, Inc. (ALDX). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

12/17/2015 – Janney Montgomery Scott began new coverage on Aldeyra Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 15 price target on the stock.

11/13/2015 – Aldeyra Therapeutics, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 15 price target on the stock.

09/08/2015 – Cowen began new coverage on Aldeyra Therapeutics, Inc. giving the company a “outperform” rating. They now have a USD 15 price target on the stock.

08/13/2015 – Aldeyra Therapeutics, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 13 price target on the stock.

03/25/2015 – Chardan Capital began new coverage on Aldeyra Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 16 price target on the stock.

01/26/2015 – Laidlaw began new coverage on Aldeyra Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 30 price target on the stock.

12/03/2014 – Ascendiant Capital Markets began new coverage on Aldeyra Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 16 price target on the stock.

06/19/2014 – Aegis Capital began new coverage on Aldeyra Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 35 price target on the stock.

The share price of Aldeyra Therapeutics, Inc. (ALDX) was down -1.90% during the last day of trading, with a day high of 6.26. 58770 shares were traded during the last session.

The stock’s 50 day moving average is 5.30 and its 200 day moving average is 5.76. The stock’s market capitalization is 38.66M. Aldeyra Therapeutics, Inc. has a 52-week low of 3.39 and a 52-week high of 10.90.

View other investors thoughts on Aldeyra Therapeutics, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.